Clinical Validation of a Serum Protein Panel (FLNA, FLNB and KRT19) for Diagnosis of Prostate Cancer
Journal of Molecular Biomarkers and Diagnosis, 2017, 8:2, 323. Ravipaty, et al. BERG, LLC, collaborated with Mount Sinai Hospital Toronto to develop and test a novel serum protein panel of three prostate cancer biomarkers for use in prostate cancer screening and diagnosis.
Authors: Shobha Ravipaty, Wenfang Wu, Aditee Dalvi, Nikunj Tanna, Joe Andreazi, Tracey Friss, Allison Klotz, Chenchen Liao, Jeonifer Garren, Sally Schofield, Eleftherios P Diamandis, Eric A Klein, Albert Dobi, Shiv Srivastava, Poornima Tekumalla, Michael A Kiebish, Vivek K Vishnudas, Rangaprasad Sarangarajan, Niven R Narain, and Viatcheslav R Akmaev
Prostate cancer is a leading cause of cancer deaths in men. Current testing for this disease includes screening for prostate-specific antigen (PSA) from blood samples, a digital rectal exam and a diagnostic prostate biopsy. These tests are invasive for patients, and the PSA test itself is often inaccurate in distinguishing between low risk and aggressive disease, subjecting many patients to unnecessary treatment. BERG, LLC, developed a panel of biomarkers for improved prostate cancer diagnosis to classify patients with disease from those that are healthy, or patients with different types of disease. We developed new methods of detection of the biomarker panel using a mass spectrometry approach, and collaborated with Mount Sinai Hospital in Toronto to analyze over 500 patient samples. We found our biomarker panel outperformed than the current standard of diagnosis, the PSA test, in distinguishing between low risk and aggressive cancers, and between benign prostate hyperplasia and cancer in patient samples.